National Health Determination under paragraph 98C(1)(b) Amendment 2017 (No. 3) (PB 28 of 2017) (Cth)

PB 28 of 2017

National Health Determination under paragraph 98C(1)(b) Amendment 2017
(No. 3)

_____________________________________________________________________

I, LOUISE CLARKE, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

Dated 27 April 2017

LOUISE CLARKE

First Assistant Secretary (Acting)

Pharmaceutical Benefits Division

Department of Health

1              Name of Instrument

(1)This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2017 (No. 3).

(2)This Instrument may also be cited as PB 28 of 2017.

2              Commencement  

This instrument commences on 1 May 2017.

3              Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

Schedule 1            Amendments

1. Schedule 3, after entry for Oxycodone with naloxone in the form Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg

insert in the column headed “Form (strength, type, size, etc.)”:

Tablet (controlled release) containing oxycodone hydrochloride 60 mg with naloxone hydrochloride 30 mg

Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg

1. Schedule 4, after entry for Cephalexin in the form Granules for oral suspension 250 mg per 5 mL, 100 mL

insert:

Chloramphenicol Eye drops 5 mg per mL, 10 mL